Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bhumiamalaki + Siddha Makardwaja is an Ayurvedic combination therapy primarily investigated for the treatment of Non-Alcoholic Steatohepatitis (NASH) and liver fibrosis. The therapy consists of Bhumiamalaki (*Phyllanthus niruri*), an aqueous herbal extract known for its antifibrotic and hepatoprotective properties, and Siddha Makardwaja Rasa, a traditional metallic preparation containing gold nanoparticles (Au/HgO) that acts as a systemic anti-inflammatory agent. The combination is designed to target multiple pathways, including the regulation of hepatic lipid metabolism, reduction of pro-inflammatory cytokines, and the reversal of liver stiffness and fibrosis. Clinical case studies have demonstrated its potential to reduce Liver Stiffness Measurement (LSM) and Controlled Attenuation Parameter (CAP) scores in patients with NASH.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bhumiamalaki + siddha makardwaja.